Prebiotic Therapy to Improve Outcomes of Renal Transplant

About This Study

This randomized, double-blind, pilot study evaluates the safety and efficacy of human milk oligosaccharides (HMO) in approximately 60 patients undergoing kidney transplantation. Participants receive either HMO prebiotic sachets or placebo for 12 weeks to determine if prebiotic therapy reduces delayed graft function and mitigates gastrointestinal side effects associated with post-transplant immunosuppression. The study monitors graft function through serial blood and urine samples, while microbiome changes are assessed via fecal analysis at six time points. Researchers utilize SF-36 and GI health questionnaires to measure quality of life and treatment tolerability over a six-month follow-up period. The primary objective is to determine if HMO-driven production of short-chain fatty acids improves the gut-kidney axis and stabilizes systemic inflammatory responses in this population.